October 2022: SwiftDx announced the launch of new mycoplasma contamination testing. It is a lateral flow test, that had adopted the PCR techniques. It is easier to use and provides accurate results within minutes. The test has been fully evaluated and validated by the University of Cambridge.
April 2023: Agathos Biologics announced the launch of advanced analytical testing services for research in the field of life sciences. It employs digital PCR (dPCR) technology to provide the most accurate sensitivity and precision in nucleic acid measurement.
Author Credits: Abhishek Verma, Hetal Singh
Report ID: 4969
Published Date: Jun 01, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Increasing expenditure on new biotech research, advancing technology of mycoplasma testing, and globalization of research are the major factors driving the market growth.
The market size of mycoplasma testing is anticipated to attain a CAGR of ~12% over the forecast period, i.e., 2023 â€“ 2035.
T he major players in the market are Thermo Fisher Scientific, Inc, Merck KGaA,, Lonza Group Ltd., PromoCell GmbH, Asahi Kasei Corporation, Sartorius AG, InvivoGen, Eurofins Scientific, SwiftDx, and Agathos Biologics.
The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by application, technique, product & services, end user.
The cell line segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Lack of skilled workers and high cost of testing are estimated to be the growth hindering factors for the market expansion.
The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.